Table 1.
Patient demographics
| BOS | Non‐BOS | p‐value | |
|---|---|---|---|
| Number of patients | 25 | 25 | |
| Median age (years) | 46 (23–63) | 45 (19–64) | p = 0.47 |
| Sex distribution | |||
| Male | 15 | 20 | p = 0.12 |
| Female | 10 | 5 | |
| Number of acute rejection episodes | 22 | 21 | p = 0.35 |
| Median number of BAL samples per patient | 5 (2–8) | 3 (2–4) | p < 0.001 |
| Underlying condition | BOS | Non‐BOS | p‐value | ||
|---|---|---|---|---|---|
| Number | % | Number | % | ||
| COPD | 9 | 36% | 2 | 8% | p = 0.37 |
| Cystic fibrosis | 6 | 24% | 11 | 44% | |
| Fibrotic lung disease | 5 | 20% | 8 | 32% | |
| α1‐Anti‐trypsin deficiency | 2 | 8% | 2 | 8% | |
| Asthma | 1 | 4% | 0 | 0% | |
| Histiocytosis | 1 | 4% | 0 | 0% | |
| Lymphangioleiomyomatosis | 1 | 4% | 0 | 0% | |
| Primary pulmonary hypertension | 0 | 0% | 1 | 4% | |
| Bronchiectasis | 0 | 0% | 1 | 4% | |
| Type of transplant | BOS | Non‐BOS | p‐value | ||
|---|---|---|---|---|---|
| Number | % | Number | % | ||
| Single lung | 9 | 36% | 7 | 28% | p = 0.40 |
| Bilateral lung | 16 | 64% | 17 | 68% | |
| Heart lung | 0 | 0% | 1 | 4% | |
| Organisms cultured from BAL | BOS | Non‐BOS | p‐value | ||
|---|---|---|---|---|---|
| Number | % | Number | % | ||
| Pseudomonas aeruginosa | 5 | 20% | 7 | 28% | p = 0.25 |
| Candida albicans | 9 | 36% | 11 | 44% | |
| Aspergillus fumigatus | 5 | 20% | 0 | 0% | |
| Proteus mirabilis | 1 | 4% | 0 | 0% | |
| Stenotrophomonas maltophilia | 3 | 12% | 0 | 0% | |
| Staphylococcus aureus | 2 | 8% | 3 | 12% | |
| Acinetobacter baumannii | 1 | 4% | 0 | 0% | |
| Aspergillus nidulans | 1 | 4% | 0 | 0% | |
| Enterobacter cloacae | 1 | 4% | 0 | 0% | |
| Haemophilus influenzae | 1 | 4% | 0 | 0% | |
| Klebsiella pneumonia | 1 | 4% | 0 | 0% | |
| Serratia spp | 1 | 4% | 1 | 4% | |
| MRSA | 0 | 0% | 3 | 12% | |
| Escherichia coli | 0 | 0% | 2 | 8% | |
| Burkholderia cepacia complex | 0 | 0% | 1 | 4% | |
| Exophiala spp | 0 | 0% | 1 | 4% | |
| No organisms cultured | 11 | 44% | 5 | 20% | |
BAL, bronchoalveolar lavage; BOS, bronchiolitis obliterans syndrome; COPD, chronic obstructive pulmonary disease; MRSA, methicillin‐resistant Staphylococcus aureus.